Navigation Links
Savient Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference
Date:2/17/2012

EAST BRUNSWICK, N.J., Feb. 17, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Citi 2012 Global Health Care Conference on Tuesday, February 28, 2012 at 8:30 AM Eastern Time.  The conference will be held at the Waldorf Astoria Hotel in New York City.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT - GContact: Mary Coleman

Carney NoensieSavient Pharmaceuticals, Inc.

Burns McClellaninformation@savient.com  

cnoensie@burnsmc.com(732) 418-9300

(212) 213-0006 


'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
2. Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
3. Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
4. Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
5. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
6. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
7. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
8. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
9. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
10. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
11. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... aTyr Pharma, Inc. (Nasdaq: LIFE ), a biotherapeutics company ... severe, rare diseases, today announced that senior management will participate in ... Conference at the InterContinental Barclay Hotel in New York ... ET. About aTyr Pharma ... aTyr Pharma is engaged in the ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, Inc. ... (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) to ... for the treatment of bacterial infections including those ... recognized as an attractive antibacterial target for more ... of suitable chemical starting points has hampered its ...
(Date:12/8/2016)... -- The global biosurgery market is expected to grow at ... 2016 to 2021. The market is poised to reach ... in 2016. The market is primarily driven by rising ... and spinal problems, increasing clearance of biosurgery products by ... management. In this report, the biosurgery market ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... The Florida Hospital Tampa Wound Healing ... Society (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute ... and facilities have earned this distinction. This is the second time the Florida ...
(Date:12/8/2016)... JENNERSVILLE, Pa. (PRWEB) , ... December 08, 2016 ... ... Penn Medicine Southern Chester County, a Property owned by an affiliate of Seavest, ... 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman ... law firm Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at ... DeviceTalks series, and attorneys from the firm’s global Life Sciences & Medical Technology Group ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... development solutions for drugs, biologics and consumer health products, today announced that it ... up in 2006 as a non-profit organization to unite pharmaceutical and healthcare companies ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
Breaking Medicine News(10 mins):